öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÁõ°®Èº
ÐÔ±ð£ºÅ®
ÈËÆøÖ¸Êý£º216

ËùÊôԺУ£º¹ãÎ÷Ò½¿Æ´óѧ
ËùÊôԺϵ£ºÖ×ÁöҽѧԺ
Ö°³Æ£ºÖ÷ÈÎҽʦ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÄÚ¿Æѧ¡¢ÄÚ¿Æѧ(öλÔÓéÀֵǼÈë¿ÚÏÂÔØÐÍ)
Ñо¿ÁìÓò£º Ïû»¯µÀ¡¢ºôÎüµÀÖ×ÁöµÄÁÙ´²Óë»ù´¡Ñо¿
Ñо¿ÁìÓò£º Ïû»¯µÀ¡¢ºôÎüµÀÖ×ÁöµÄÁÙ´²Óë»ù´¡Ñо¿ [ÊÕÆð]




¸öÈ˼òÊö :
Áõ°®Èº£¬Å®£¬Ö÷ÈÎҽʦ£¬Ò½Ñ§²©Ê¿£¬Ë¶Ê¿Ñо¿Éúµ¼Ê¦¡£Öйú¿¹°©Ð­»áÖ×ÁöÄÚ¾µöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£»Öйش壨·ºÑÇ£©Ïû»¯ÄÚ¾µ¼¼Êõ´´ÐÂÕ½ÂÔÁªÃËÀíÊ£»¹ãÎ÷ҽѧ»áºôÎüÄÚ¾µÐ­»á³£ÎñίԱ£»¹ãÎ÷ҽѧ»áÏû»¯ÄÚ¾µÑ§»áίԱ£»¹ãÎ÷¿¹°©Ð­»áÓ°ÏñѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ¡£ÊìÁ·ÕÆÎÕÁËÏû»¯µÀ¡¢ºôÎüµÀÖ×ÁöµÄÄÚ¾µÏÂÕï¶ÏÓëÖÎÁÆ¡£ÔÚ¹ãÎ÷ÇøÄÚÂÊÏÈ¿ªÕ¹ÁË¡°³¬ÉùÖ§Æø¹Ü¾µÒýµ¼ÏÂÕëÎü»î¼ìÊõÔڷΰ©Õï¶ÏÖеÄÓ¦Óá±£¬Ìí²¹ÁËÇøÄÚ¿Õ°×£¬Ïà¹ØµÄÑо¿³É¹û·¢±íÔÚ¡¶ÖйúÄÚ¾µÔÓÖ¾¡·¡¢¡¶Î¢´´Ò½Ñ§¡·¡¢¡¶ÖлªÈ«¿ÆҽѧÔÓÖ¾¡·µÈöλÔÓéÀֵǼÈë¿ÚÏÂÔØѧÊõÆÚ¿¯¡£Í¬Ê±¿ªÕ¹ÁËθ°©¡¢´ó³¦°©Ïû»¯µÀÖ×ÁöµÄ»ù´¡ÓëÁÙ´²Ñо¿£¬Ïà¹ØÑо¿³É¹û·¢±íÔÚ,¡¶oncotarget¡·¡¶PLoS?ONE¡·¡¢¡¶Gastroenterology?Research?and?Practice¡·µÈSCIÆÚ¿¯¡£

¿ÆÑй¤×÷ :
½üÄêÀ´³Ðµ£ºÍ²ÎÓëÊ¡Ìü¼¶¿ÆÑÐÏîÄ¿Ê®ÓàÏî¡£ÒÔµÚÒ»×÷Õß»òͨѶ×÷ÕßÔÚ¹úÄÚºËÐÄöλÔÓéÀֵǼÈë¿ÚÏÂÔØÆÚ¿¯·¢±íÂÛÎÄÈýÊ®¶àƪ£¬SCIÂÛÎÄ5ƪ£¬»ñ¹ãÎ÷Ò½Ò©ÎÀÉúÊÊÒ˼¼ÊõÍƹ㽱¶þµÈ½±1Ïî¡¢¹ãÎ÷¿Æ¼¼½ø²½ÈýµÈ½±1Ïî¡£²Î±à½Ì²ÄÒ»²¿¡£2015Äê¶ÈÖÁ2016Äê¶ÈÔÚÃÀ¹ú¸¥¼ªÄáÑÇ´óѧ°©Ö¢Ñо¿ÖÐÐIJ¡Àíѧϵ·ÃѧһÄ꣬Ñо¿Î¸°©µÄ·¢²¡»úÖÆ¡£1.?Ai-qun?Liu,?Zhong-qiu?Xie,?Xiao-ni?Chen,?Jie?Feng,?Jia-wei?Chen,?Fu-jun?Qin,?Lian-ying?Ge.?Fas-associated?factor?1?inhibits?tumor?growth?by?suppressing?Helicobacter?pylori-induced?activation?of?NF-¦ÊB?signaling?in?human?gastric?carcinoma?.oncotarget,2016,1-7.(?SCI?,IF=5.008)2.??Liu?A-Q#*,?Ge?L-Y,?Lu?X-L,?Luo?X-L,?Cai?Y-L,Ye?X-Q,Geng?F-F.Silencing?of?the?hTERT?Gene?by?shRNA?Inhibits?Colon?Cancer?SW480?Cell?Growth?In?Vitro?and?In?Vivo.??PLoS?ONE?9(9):e107019,?2014.?(SCI,?IF=3.542)3.??Ai-qun?Liu,?Lian-ying?Ge*,?Xin-qing?Ye,?Xiao-ling?Luo,?and?Yuan?Luo.?Reduced?FAF1?Expression?and?Helicobacter?Infection:?Correlations?with?Clinicopathological?Features?in?Gastric?Cancer.?Gastroenterology?Research?and?Practice,?2012,?153219,?2012.?(SCI,?IF=1.615)4.??JIA-XIANG?YE#,?AI-QUN?LIU#,?LIAN-YING?GE,?SHAO-ZHANG?ZHOU?and?ZHONG?GUO?LIANG.?Effectiveness?and?safety?profile?of?S?1?based?chemotherapy?compared?with?capecitabine?based?chemotherapy?for?advanced?gastric?and?colorectal?cancer:?A?meta?analysis.?Experimental?and?therapeutic?medicine,?7:?1271-1278,?2014.?(SCI,?IF=1.269)5.?³ÂСÄÝ,?Áõ°®Èº£ª,?¸ðÁ«Ó¢?.?ÓÄÃÅÂݸ˾ú¸ÐȾͨ¹ýºËÒò×Ó¦ÊBÐźÅͨ·µ÷¿ØFasÏà¹ØÒò×Ó1±í´ïµÄÏà¹Ø»úÖÆ.?ÊÀ½ç»ªÈËÏû»¯ÔÓÖ¾£¬2016?24(9):?1405-1411?.6.?³ÂÉý£¬Áõ°®Èº£ª£¬ÁõÁ¢ÒåµÈ.³¬ÉùÖ§Æø¹Ü¾µÒýµ¼ÏÂÕëÎü»î¼ìÊõ½áºÏÃâÒß×黯¼°»ùÒòѧ¼ì²âÔڷΰ©ÕïÖÎÖеÄÓ¦ÓÃ.ÖйúÄÚ¾µÔÓÖ¾£¬2016£¬5£¨22£©£¬6-11.7.?Éòåû»ª£¬Áõ°®Èº£ª.³¬ÉùÄÚ¾µÔÚÏû»¯ÏµÍ³¼²²¡½éÈëÕï¶ÏºÍÖÎÁÆÑо¿µÄнøÕ¹,?ÊÀ½ç»ªÈËÏû»¯ÔÓÖ¾£¬2016£¬6:833-841.8.?Áõ°®Èº#*£¬¸ðÁ«Ó¢.EUS-FNAºÍEBUS-TBNAÔÚÏû»¯µÀºÍºôÎüµÀÖ×ÁöÕï¶ÏÖÎÁÆнøÕ¹.ÖйúÄÚ¾µÔÓÖ¾£¬2015,1£¨21£©:46-50.9.Áõ°®Èº#,¸ðÁ«Ó¢,¹¢·¼·¼,Ò¶ÐÂÇà,Éòåû»ª,ÀîÀö÷,ÁõÁ¢Òå.?EUS-FNAºÍEBUS-TBNAÁªºÏÕï¶Ï×ݸô²¡±äµÄÓ¦ÓÃ̽ÌÖ.?΢´´Ò½Ñ§,2014,9(3):270-27210.?Éòåû»ª#,?Áõ°®Èº*,?ÁõÁ¢Òå,?¹¢·¼·¼.³¬ÉùÄÚ¾µ¶Ôµ¨×ܹÜÁ¼¶ñÐÔÏÁÕ­µÄ¼ø±ðÕï¶Ï¼ÛÖµ.?ÊÀ½ç»ªÈËÏû»¯ÔÓÖ¾£¬2015,23(30):?4892-4897.11.Áõ°®Èº#*£¬¸ðÁ«Ó¢.ÓÄÃÅÂݸ˾ú¸ÐȾÏà¹Øθ°©µÄϸ°ûÄÚÐźÅתµ¼Í¨Â·Ñо¿ÏÖ×´.¹ãÎ÷Ò½¿Æ´óѧѧ±¨,2014,31(1):150-152.?12.?Áõ°®Èº£¬»ÆÄÈ£¬¸ðÁ«Ó¢£¬ÁõÁ¢ÒåµÈ.ÎïÀíÕï¶ÏѧPBL»ìºÏʽ½ÌѧģÐͼ°×ÊԴƽ̨¹¹½¨¡£»ù´¡Ò½Ñ§£¬2014£¬16£¨1£©:37-39.??13.Áõ°®Èº£¬¸ðÁ«Ó¢£¬ÁõÁ¢ÒåµÈ.PBL½ÌѧģʽÔÚÎïÀíÕï¶Ïѧ½ÌѧÖеÄÓ¦Ó᣻ù´¡Ò½Ñ§£¬2014,?16(5):382-385.??14.?Áõ°®Èº£¬¸ðÁ«Ó¢£¬¹¢·¼·¼µÈ.?ÓÄÃÅÂݸ˾ú¸ÐȾθ°©±ä¹ý³ÌÖÐSurvivin?mRNAµÄ±í´ï¼°ÆäÓëµòÍöµÄ¹Øϵ.¹ã¶«Ò½Ñ§£¬2013,34(sup):76-78.??15.?Áõ°®Èº£¬¸ðÁ«Ó¢£¬Î¤×ÚƼ.θ°©±ä¹ý³ÌÖÐBcl-2?mRNAÓëÓÄÃÅÂݸ˾ú¸ÐȾ¼°Ï¸°ûµòÍöµÄ¹Øϵ.ɽ¶«Ò½Ò©£¬2013,53(10):41-43.16.Áõ°®Èº#*£¬¸ðÁ«Ó¢£¬ÂÞÔª£¬ÁÖ˼ͮ.FasÏà¹ØÒò×Ó1ÔÚÓÄÃÅÂݸ˾ú¸ÐȾθ°©±ä¹ý³ÌÖеıí´ï¼°ÆäÓëµòÍöµÄ¹Øϵ.?ÖлªÊµÑéÍâ¿ÆÔÓÖ¾,2012,29£¨6£©:1133.?17.?¸ðÁ«Ó¢#£¬Áõ°®Èº*£¬ÂÞСÁá,²ÌÑÞÁᣬ¹¢·¼·¼.RNA¸ÉÈųÁĬÈ˶ËÁ£Ã¸Äæת¼ø»ùÒòÖÎÁƴ󳦰©ÒÆÖ²Áö.?ÖлªÊµÑéÍâ¿ÆÔÓÖ¾£¬2012,29£¨10£©:2012-2014.?